Want to see ANGO full AI Analyst Report?
Top Page
AngioDynamics
(NASDAQ:ANGO)
Select Model
Select Model
Rating:62Neutral
Price Target:
$15.50
▲(14.05% Upside)
Action:Reiterated
Date:07/16/26
ANGO scores moderately due to strong technical momentum (price above key moving averages with positive MACD) and a supportive earnings outlook pointing to continued Med Tech-driven growth and margin/EBITDA improvement. The score is held back primarily by weak financial performance from ongoing net losses and negative returns, plus limited valuation support given the negative P/E and no dividend yield provided.
Positive Factors
Med Tech Platform Growth
Sustained, above-market Med Tech growth shifts the revenue mix toward higher-growth, higher-margin products. Durable procedure-driven consumable demand (Auryon, NanoKnife, AlphaVac) supports recurring sales, improving top-line quality and the company's ability to scale commercial investments over the next several quarters.
Negative Factors
Persistent GAAP Losses
Ongoing GAAP losses reflect that operating profitability has not yet been achieved on a GAAP basis, pressuring returns and limiting retained earnings. Until GAAP profitability is sustained, equity value and ability to fund expansion without dilution remain vulnerable despite adjusted improvements.
Read all positive and negative factors
Positive Factors
Negative Factors
Med Tech Platform Growth
Sustained, above-market Med Tech growth shifts the revenue mix toward higher-growth, higher-margin products. Durable procedure-driven consumable demand (Auryon, NanoKnife, AlphaVac) supports recurring sales, improving top-line quality and the company's ability to scale commercial investments over the next several quarters.
Read all positive factors
AngioDynamics (ANGO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$610.48M
Dividend YieldN/A
Average Volume (3M)498.60K
Price to Earnings (P/E)―
Beta (1Y)0.26
Revenue Growth9.46%
EPS Growth-6.34%
CountryUS
Employees675
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.88
Shares Outstanding41,332,390
10 Day Avg. Volume714,359
30 Day Avg. Volume498,601
Financial Highlights & Ratios
PEG Ratio-2.06
Price to Book (P/B)2.65
Price to Sales (P/S)1.42
P/FCF Ratio891.83
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue1.40
Enterprise Value/Gross Profit2.56
Enterprise Value/Ebitda-12.42
Forecast
1Y Price Target
$21.00Price Target Upside54.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$329.59M
AngioDynamics Business Overview & Revenue Model
Company Description
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as per...
How the Company Makes Money
AngioDynamics makes money primarily by selling medical devices to hospitals, outpatient centers, and other healthcare providers, with revenue generally recognized from product sales (typically upon delivery/transfer of control depending on contrac...
AngioDynamics Earnings Call Summary
Earnings Call Date:Jul 14, 2026
(Q4-2026)
| % Change Since: |
Next Earnings Date:Oct 01, 2026
Earnings Call Sentiment Positive
The call emphasized strong, above-market growth in Med Tech platforms (notably NanoKnife, Auryon, and AlphaVac), improving gross margins and a materially higher adjusted EBITDA for the year, plus a debt-free balance sheet and positive cash generation in Q4. Offsetting these positives are ongoing GAAP losses, tariff headwinds (~$4.8M), higher operating expenses, lumpiness in some product lines (AngioVac, capital equipment), and modest full-year cash generation. Management provided constructive FY2027 guidance with continued Med Tech growth and maintained investments in clinical R&D. Overall, the positive operational momentum, clinical progress, margin expansion, and improved adjusted EBITDA notably outweigh the headwinds and remaining losses.Positive Updates
Top-line Revenue Growth - Q4 and Full Year
Total revenue increased 8% in Q4 to $86.6M and rose 9.4% for fiscal 2026 to $320.2M, driven primarily by Med Tech strength.
Negative Updates
GAAP Net Losses and Adjusted Losses Persist
GAAP net loss in Q4 was $11.4M (loss per share $0.27) vs $6.1M a year ago; full-year GAAP net loss was $36.7M (loss per share $0.88) vs $34.0M prior year. Adjusted net loss Q4 was $2.8M (vs $1.1M prior year) and adjusted net loss for FY2026 was $10.0M (vs $10.2M).
Read all updates
Q4-2026 Updates
Positive
Negative
Top-line Revenue Growth - Q4 and Full Year
Total revenue increased 8% in Q4 to $86.6M and rose 9.4% for fiscal 2026 to $320.2M, driven primarily by Med Tech strength.
Read all positive updates
Company Guidance
For fiscal 2027 AngioDynamics guided net sales of $336.0–$341.0 million (up about 5.0%–6.5% vs FY2026 revenue of $320.2M), calling for Med Tech growth of 12%–15% and Med Device roughly flat; gross margin of 54%–55%; adjusted EBITDA of $13M–$16M; and an adjusted loss per share of $0.29–$0.24, with tariff expense expected to be broadly similar to FY2026 (FY2026 tariffs ≈ $4.8M and were guided initially at $4M–$6M); management also reiterated a target of roughly 10% of sales for R&D investment while seeking to convert above‑market Med Tech growth into increasing profitability and positive cash generation.AngioDynamics Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
68
Positive
Cash Flow
46
Neutral
| Breakdown | May 2026 | May 2025 | May 2024 | May 2023 | May 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 320.17M | 292.50M | 303.91M | 338.75M | 316.22M |
| Gross Profit | 174.89M | 157.71M | 154.70M | 174.25M | 165.73M |
| EBITDA | -36.00M | 1.74M | -6.13M | 12.19M | 11.13M |
| Net Income | -36.74M | -33.99M | -184.35M | -52.44M | -26.55M |
Balance Sheet | |||||
| Total Assets | 267.16M | 280.14M | 317.67M | 532.64M | 552.75M |
| Cash, Cash Equivalents and Short-Term Investments | 53.86M | 55.89M | 76.06M | 44.62M | 28.82M |
| Total Debt | 0.00 | 10.15M | 4.73M | 64.58M | 33.78M |
| Total Liabilities | 96.34M | 97.17M | 112.08M | 154.34M | 128.26M |
| Stockholders Equity | 170.82M | 182.97M | 205.59M | 378.30M | 424.49M |
Cash Flow | |||||
| Free Cash Flow | 508.00K | -14.59M | -33.93M | -4.27M | -11.49M |
| Operating Cash Flow | 3.09M | -10.13M | -28.16M | 78.00K | -7.19M |
| Investing Cash Flow | -5.95M | -10.18M | 123.72M | -9.75M | -19.31M |
| Financing Cash Flow | 564.00K | -255.00K | -64.25M | 25.42M | 7.68M |
AngioDynamics Technical Analysis
Positive
13.59
Price Trends
12.78
Positive
11.78
Positive
11.78
Positive
Market Momentum
0.38
Positive
55.56
Neutral
45.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANGO, the sentiment is Positive. The current price of 13.59 is below the 20-day moving average (MA) of 13.67, above the 50-day MA of 12.78, and above the 200-day MA of 11.78, indicating a bullish trend. The MACD of 0.38 indicates Positive momentum. The RSI at 55.56 is Neutral, neither overbought nor oversold. The STOCH value of 45.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ANGO.
AngioDynamics Risk Analysis
AngioDynamics disclosed 34 risk factors in its most recent earnings report. AngioDynamics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AngioDynamics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $221.51M | 21.90 | 8.74% | 1.84% | -7.00% | ― | |
67 Neutral | $312.12M | -8.69 | -246.44% | ― | 17.41% | -189.91% | |
62 Neutral | $610.48M | -16.81 | -21.01% | ― | 9.46% | -6.34% | |
60 Neutral | $185.47M | 24.03 | 14.00% | ― | 3.50% | 157.81% | |
54 Neutral | $273.33M | -3.89 | -21.50% | ― | -30.08% | -143.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $130.25M | -5.16 | -153.21% | ― | 13.40% | 20.97% |
* Healthcare Sector Average
ANGO
AngioDynamics
14.79
6.23
72.78%
INFU
InfuSystem Holdings
9.14
3.44
60.35%
OSUR
Orasure Technologies
4.05
1.04
34.55%
STXS
Stereotaxis
1.26
-0.96
-43.24%
UTMD
Utah Medical Products
70.52
16.65
30.90%
SMTI
Sanara MedTech
33.86
9.70
40.15%
AngioDynamics Corporate Events
Business Operations and StrategyFinancial Disclosures
AngioDynamics posts record Q4 and fiscal 2026 results
Positive
Jul 15, 2026
AngioDynamics reported record financial results for its fiscal fourth quarter and full year ended May 31, 2026, highlighting a seventh consecutive quarter of double-digit Med Tech growth and positive adjusted EBITDA. Pro forma net sales rose 8.0% ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.